FTC Threat to Block $3.5 Billion Covetrus-MWI Deal Raises Stakes for M&A Traders
A reported FTC lawsuit over the $3.5 billion Covetrus-MWI deal highlights regulatory risk for merger arbitrage and healthcare distribution.
Viking Therapeutics Takeover Chatter Puts VKTX Back in the M&A Spotlight
Renewed takeover interest lifted VKTX shares, sharpening the debate over obesity-drug consolidation and the risks of M&A-driven repricing.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
October PPI Cools Slightly Against Expectations, Keeping Fed Rate Bets in Focus
October producer prices came in slightly below expectations, offering a nuanced signal for Federal Reserve policy watche…
FTC Challenge Puts $3.5 Billion Covetrus-MWI Deal in Doubt
A reported FTC plan to block Covetrus-MWI’s $3.5 billion merger raises deal-timing, completion-risk and consolidation co…
Sellas Life Sciences Surges 17% Ahead of Potentially Transformative AML Data
Sellas Life Sciences shares jumped 17% after hours as investors positioned for the company’s expected Phase 3 AML readou…
Candel Therapeutics Target Cut to $19 as BLA Delay Raises Regulatory Risk
Stifel cut Candel Therapeutics’ target to $19 after a BLA delay, while the biotech continues FDA discussions and readine…
Rezolute Stock Jumps 7.8% as Tumor Hypoglycemia Data Set Up FDA Catalyst
Rezolute shares rose 7.8% pre-market after tumor hypoglycemia data, with FDA discussions planned for Q1 2027 as topline …
Denali Therapeutics Gets Bullish Wells Fargo Initiation on Hunter Syndrome Drug
Wells Fargo initiated Denali Therapeutics at overweight, putting fresh sell-side attention on its approved Hunter Syndro…
Altimmune’s Wider Q3 Loss Puts the Spotlight on Its $480 Million Clinical Runway
Altimmune’s wider Q3 loss sharpens the balance-sheet debate as $480 million supports pemvidutide’s ongoing liver-disease…
FDA Fast-Track Shutdown Raises Approval-Timeline Risks for Biotech Investors
The reported end of the FDA Fast-Track program could lengthen approval timelines, while SPY valuation reportedly remaine…
Biotech Traders Face a Year-End Wave of FDA Catalysts for BBIO and VRTX
Priority reviews for BBIO and VRTX create a concentrated late-2026 FDA calendar spanning muscle disease, kidney disease,…